Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Lori Goldstein

Email
Center AffiliationsMolecular Therapeutics

Publications (101) (print view)

no pagination
Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): A trial of the eastern cooperative oncology group. Cancer Investigation. 2006 Nov;24(7):677-81.
Freedman GM, Anderson P, Li TY, Ross E, Swaby R, Goldstein L. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen. Cancer. 2006 Dec;107(11):2552-8.
Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clinical Breast Cancer. 2006 Feb;6 Suppl 2:S36-40.
Manne SL, Ostroff JS, Norton TR, Fox K, Goldstein L, Grana G. Cancer-related relationship communication in couples coping with early stage breast cancer. PSYCHO-ONCOLOGY. 2006 Mar;15(3):234-47.
Manne SL, Ostroff JS, Norton TR, Fox K, Grana G, Goldstein L. Cancer-specific self-efficacy and psychosocial and functional adaptation to early stage breast cancer. Ann Behav Med. 2006 Apr;31(2):145-54.
Morrow M, Goldstein L. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted?. J Clin Oncol. 2006 Jun 20;24(18):2694-6.
Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. The oncologist. 2004 Jan;9 (6):606-16.
Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clinical Cancer Research. 2004 Nov;10(21):7220-8.
Manne S, Ostroff J, Rini C, Fox K, Goldstein L, Grana G. The Interpersonal Process Model of Intimacy: The Role of Self-Disclosure, Partner Disclosure, and Partner Responsiveness in Interactions Between Breast Cancer Patients and Their Partners. Journal of Family Psychology. 2004 Jan;18(4):589-99.
Manne S, Ostroff J, Winkel G, Goldstein L, Fox K, Grana G. Posttraumatic growth after breast cancer: Patient, partner, and couple perspectives. Psychosomatic Medicine. 2004 May;66(3):442-54.
Sundermeyer ML, Goldstein LJ. American Society for Clinical Oncology 40th annual meeting, New Orleans, LA, 5-8 June 2004: breast cancer highlights. Breast Cancer Research. 2004 Jan;6(6):275-8.
Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge GW. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial. Journal of Clinical Oncology. 2004 Mar;22(6):1071-7.
Wallace SG, Goldstein LJ. Nonepithelial malignancies of the breast - The Chugh/Baker article reviewed. ONCOLOGY-NEW YORK. 2004 May;18(5):675-6.
Freedman GM, Anderson PR, Goldstein LJ, Hanlon AL, Cianfrocca ME, Millenson MM, von Mehren M, Torosian MH, Boraas MC, Nicolaou N, Patchefsky AS, Evers K. Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older. Cancer. 2003 Sep;98(5):918-25.
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976-83.
Schulman KA, Stadtmauer EA, Reed SD, Glick HA, Goldstein LJ, Pines JM, Jackman JA, Suzuki S, Styler MJ, Crilley PA, Klumpp TR, Mangan KF, Glick JH. Economic analysis of conventional-dose chemotherapy compared with high- dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Bone Marrow Transplantation. 2003 Feb;31(3):205-10.
Traut D, Goldstein LJ. Adjuvant therapy: taxanes. Journal of the National Comprehensive Cancer Network. 2003 Jan;1(2):222-9.
Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul;21(13):2597-9.
Russin MP, Goldstein LJ. Chemotherapy in breast cancer. In: Torosian M, editor. Breast cancer : a guide to detection and multidisciplinary therapy. Totowa, N.J.: Humana Press; 2002. p. 145-59.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug;20(15):3317-27.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Lori Goldstein Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Friday, December 06, 2019